Slide 1: Setting the pace … Bringing Probabilities of Success up
Setting the pace … Bringing Probabilities of Success up with the right platforms & technologies Evotec SE, Full-year 2021 results, 12 April 2022
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicat
Slide 3: Welcome – The Management Team
Welcome The Management Team Werner Lanthaler Enno Spillner Craig Johnstone Cord Dohrmann CEO CFO COO CSO PAGE 2
Slide 4: Agenda
Agenda Highlights Financial performance 2021 Scientific and operational performance 2021 Outlook and Guidance 2022 PAGE 3
Slide 5: Strong overall performance and progress in all lanes
Strong overall performance and progress in all “lanes” Highlights & lowlights 2021 Highlights Multiple new & extended integrated drug discovery & development alliances (EVOiR&D) Opening of J.POD® Redmond, WA (US); initiation of J.POD® Toulouse, France (EU) (EVOaccess) Very good progress in co-
Slide 6: AP 2025 is fully in swing and accelerated by precision medicine
AP 2025 is fully in swing and accelerated by precision medicine Action Plan 2025 in numbers 2025 2022 2018 2012 Action Plan 2025 2009 Leadership in data, science, Action Plan 2022 multimodality & access Action Plan 2016 Aspire global Action Plan 2012 Build innovation leadership Restructure for growt
Slide 7: Platforms & technologies are high-tech driven & fully integrated
Platforms & technologies are high-tech driven & fully integrated The drug discovery & development innovation hub – Capabilities & expertise overview Industry needs Capabilities & Expertise (illustrative) R&D efficiency platforms1) Precision medi- cine platforms Just – Evotec Biologics1) Right modali
Slide 8: Faster and more learning curves illustrate technology leadership
Faster and more learning curves illustrate technology leadership “Evotec inside” (selected KPI’s 2020/21) 62 142 12 24 > 250 Patent applications High-throughput screens Pre-clinical development INDiGO® programs GMP API batches candidates (PDC) >10 >200 bn >440 bn >10,000 >100 Precision platforms Dat
Slide 9: Platforms & technologies for more precision and efficiency
Platforms & technologies for more precision and efficiency Evotec today – 15 Sites & more than 4,200 employees USA Austria Italy Germany UK France ~500 ~40 ~800 ~1,050 ~950 ~900 Branford Orth an der Donau Verona (Campus Hamburg (HQ) & Abingdon Lyon Princeton Levi-Montalcini) Goettingen
Slide 10: Attracting great talent – Growth enabled by culture & values
Attracting great talent – Growth enabled by culture & values Growth of talent in 2021 > 4,800 First time > 600 new employees hired 4,198 in one year (net number) 3,572 > 80% with at least one academic qualification; > 30% PhDs 3,030 > 8 years drug discovery and 2,600 development experience on
Slide 11: Boost of expertise in high-impact areas
Boost of expertise in high-impact areas Recent key hires >30 years in >25 years >20 years McKinsey > 20 years in pharmaceutical biotechnology & Company: Senior biotechnology safety assessment industry experience Partner & global co- industry lead R&D for GSK, Novo Nordisk, Amgen, BMS,
Slide 12: More than a decade of consecutive double digit annual growth
More than a decade of consecutive double digit annual growth Results versus previous year and guidance FY 2020 FY 2021 Yoy growth reported / Guidance results results like-for-like1) March 2021 Group revenues2) € 618.0 m € 500.9 m 23% / 27% € 550 – 570 m (at constant fx-rates) (€ 627.2m) Unpartnered
Slide 13: Significant growth step up and investments towards AP 2025
Significant growth step up and investments towards AP 2025 Guidance 2022 Guidance 2022 YE 2021 Implied growth at midpoint Group revenues € 700 – 720 m € 618.0 m ~15% (at constant fx-rates1)) (€ 690 – 710 m) Unpartnered R&D2) € 70 – 80 m € 58.1 m ~30% Adjusted EBITDA3) € 105 – 120 m € 107.3 m At leas
Slide 14: Agenda
Agenda Highlights Financial performance 2021 Scientific and operational performance 2021 Outlook and Guidance 2022 PAGE 13
Slide 15: Main KPIs underline positive development
Main KPIs underline positive development Condensed income statement 2021 – Evotec SE and subsidiaries in € m1) 2021 2020 Change Revenue growth of 23% (excluding portfolio Revenues 618.0 500.9 23% and fx effects: 27%) driven by all business areas Gross margin 24.5% 25.1% – Gross margin reflects r
Slide 16: Revenue growth exceeding guidance – strong fundamentals
Revenue growth exceeding guidance – strong fundamentals Revenues & Gross margin overview Revenues (in € m) Gross margin Group revenues +27% like-for-like (in %) Base business up 20% adjusted for Base revenues Total Margin Sanofi payment in Q1 2020 Milestones, upfronts and licences Exceptionall
Slide 17: Strong organic growth pointing to healthy demand
Strong organic growth pointing to healthy demand Revenue bridge 2020 – 2021 – Evotec SE and subsidiaries in € m1) 618.0 (9.2) 23% growth of Group revenues 134.9 500.9 Organic growth of € 134.9 m 492.3 translates into growth rate of 27% (8.6) Reference point adjusted for Sanofi Toulouse payment
Slide 18: Revenues up in both segments
Revenues up in both segments Segment information 2021 – Evotec SE and subsidiaries in € m1) Inter- EVT EVT segment Evotec Total revenues show accelerated Execute Innovate elimination Group growth in fourth quarter in both segments Revenues 610.2 147.0 (139.1) 618.0 EVT Execute total revenue grow
Slide 19: Accelerating growth at year end
Accelerating growth at year end Condensed income statement Q4 2021 – Evotec SE and subsidiaries in € m1) Q4 2021 Q4 2020 Change Q4 revenue growth of 33% Revenues 187.1 140.5 33% Strong milestone contribution leading Gross margin 27.8% 26.0% – to gross margin expansion, despite ramp-up of J.POD®
Slide 20: Exscientia IPO with very strong effect on net income
Exscientia IPO with very strong effect on net income (EVOequity) Single steps from 2020 to 2021 in € m1) 215.5 14.4 (2.0) 204.3 (8.3) 6.3 25.8 (28.2) 2.6 0.6 Net Income Gross profit R&D expenses SG&A Impairments Other operating Result (net) Other non- Taxes Net Income 2020 expenses result from equit
Slide 21: Strong cash position of > €850m securing growth ambitions
Strong cash position of > € 850m securing growth ambitions Single steps from 2020 to 2021 in € m1) 858.2 14.8 (20.7) (3.5) 403.1 122.2 (118.9) 481.9 (20.7) 31 Dec 2020 Operating Capex excl. Equity Net proceeds Bank loans & Repayment of fx difference & 31 Dec 2021 cash flow finance leases Investments
Slide 22: Expanded balance sheet as solid base for future growth
Expanded balance sheet as solid base for future growth Balance sheet and liquidity – 31 December 2021 vs. 31 Dec. 2020 – Evotec SE & subsidiaries Balance sheet total Equity ratio All relevant balance sheet metrics in € m in % significantly strengthened due to profitable growth, public US offering
Slide 23: Agenda
Agenda Highlights Financial performance 2021 Scientific and operational performance 2021 Outlook and Guidance 2022 PAGE 22
Slide 24: Excellent position for continued growth
Excellent position for continued growth Major developments in 2021 (selection) EVOiR&D Multiple new and extended drug discovery and development (e.g. Abivax, EQRx, Bicycle Therapeutics, Evommune, Takeda,…) 91% repeat business, extensions, and growth within long-term partnerships > 800 partne
Slide 25: J.POD – commercial biologics manufacturing stepping up
J.POD® – commercial biologics manufacturing stepping up EVOaccess – Progress and status J.POD® Redmond, WA (US) – Facility completed in just 19 months Grand opening in August 2021 Production from a few kilograms to metric tons in the same facility Partner at every stage of the biologics value
Slide 26: Significant expansion of alliances is basis for long-term success
Significant expansion of alliances is basis for long-term success Attraction, Extension, Retention Attraction Extension Structural Retention ≥90% +25% 355 315 100 +23% 100% 283 80 80% 60 60% 40 40% 20 20% 0 0% 2019 2020 2021 2019 2020 2021 2019 2020 2021 New customers during the year No. of customer
Slide 27: Healthy demand points to continued strong growth
Healthy demand points to continued strong growth Orders versus Revenues – Evotec SE and subsidiaries in € m 700 80% Healthy demand leads to 600 70% strongest order book in company’s history 60% 500 Near-shoring and post-pan- 50% demic market shake-up result 400 in favourable environment 40% Gr
Slide 28: Despite P2X3 set back - The iceberg keeps growing
Despite P2x3 set back - The iceberg keeps growing In total >220 projects: ~180 in partnerships, >40 internal R&D projects Inflammation & Global Neuroscience & Pain Oncology Metabolic Diseases Virology Anti-bacterial Immunology1) Health SK Ph3 Jingxin bioscience Ph2 P2X3 - CC P2X3 - OAB P2X3 - DNP Ba
Slide 29: Steady stream of high-value catalysts
“Evotec Inside” Steady stream of high-value catalysts Molecule Therapeutic Area/Indication Partner Discovery Pre-clinical Phase I Phase II Phase III Selected pipeline events within next 12 – 24 months EVT201 Insomnia (GABA-A) Not Disclosed Infectious Disease (Antibody) Phase III & registration (CH
Slide 30: Precision medicine is the only path to improved medicine
Precision medicine is the only path to improved medicine Leading AI/ML driven drug discovery & development platforms Molecular patient Targeted disease models & Clinical diagnostics databases precision medicine approaches and biomarkers Re-defining health and Focus on early Precision diagnostics and
Slide 31: Deep understanding of biology for precision medicine
Deep understanding of biology for precision medicine The Evotec Molecular Patient Database (E.MPD) Tuber- Liver culosis disease Multiple rare Infectious diseases diseases Autoimmune CNS disease Kidney diseases Fibrosis Lung & Multiple cancers Inflammation Womens‘ … Health PAGE 30 EVOpanOmics: Genomi
Slide 32: E.MPD core component of alliances in CKD
E.MPD core component of alliances in CKD Example: CKD strategic drug discovery deals * 2016/17 2018/19 2020 2021 2022 Upfront Vifor funded: € 25 m Upfront Upfront Upfront Research funding 50% on all projects Research funding Research funding Research funding Milestones JV: Ne
Slide 33: Agenda
Agenda Highlights Financial performance 2021 Scientific and operational performance 2021 Outlook and Guidance 2022 PAGE 32
Slide 34: EVOequity accelerates co-owning strategy
EVOequity accelerates co-owning strategy Operational VC model – diversified portfolio with multiple shots on goal At Equity Holding (≥20%) or Significant influence Academia Partners & BRIDGEs Minority Shareholdings (<20%) Starting Attractive portfolio points to fuel with signi- External EVOequity Sp
Slide 35: Keeping the promise – ESG & Sustainability
Keeping the promise ESG & Sustainability – Measures taken in 2021 Responsible use of resources Sourcing of 100% renewable energy since January 2021 at all German sites Decision to replace heating system in building B95 in Abingdon (est. CO2e savings of ~800t /yr) EVOearth week to raise overall
Slide 36: Strong news flow to be continued …
Strong news flow to be continued … Selected latest news in Q1 2022 PAGE 35
Slide 37: Setting the pace to accelerate growth along Action Plan 2025
Setting the pace to accelerate growth along Action Plan 2025 Selected key events to watch 2022 R&D Undisrupted growth in line with AP 2025; Continued double digit growth of efficiency base business (EVOiR&D) platforms Significant capacity and value chain expansion for all modalities and sites
Slide 38: Our mid-term aspirations are "… just the beginning"
Our mid-term aspirations are “… just the beginning” 2020-2025e Key Performance Indicator goals Revenues Adjusted EBITDA1) in € m in € m >100% ≥180% 500.9 >1,000 106.6 ≥300 Unpartnered R&D Co-owned projects2) in € m >100% >100% 46.4 >100 118 >250 PAGE 37 1) before significant royalties 2) incl. Equit
Slide 39: Upcoming important dates
Upcoming important dates Financial calendar 2022 Quarterly Statement Q1 2022 11 May 2022 Virtual Annual General Meeting 2022 22 June 2022 Half-year 2022 Interim Report 11 August 2022 Quarterly Statement 9M 2022 09 November 2022 Full annual report and sustainability report 2021 available for download
Slide 40: Slide 40
Slide 41: Appendix
Appendix PAGE 40
Slide 42: Profit & Loss Statement 31 December 2021
Profit & Loss Statement 31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated in k€ except share and per share data Year ended 31 December 2021 Year ended 31 December 2020 Revenues 618 034 500 924 Costs of revenue (466 491) (375 181) Gross profit 151 543 125 743 Operating income and (expenses)
Slide 43: Balance Sheet 31 December 2021
Balance Sheet 31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated in k€ as of 31 December 2021 as of 31 December 2020 ASSETS Current assets Cash and cash equivalents 699 326 422 580 Investments 158 908 59 350 Trade accounts receivables 132 078 79 005 Prepaid expenses and other current assets
Slide 44: Cash Flow Statement 31 December 2021
Cash Flow Statement 31 December 2021 vs. 31 Dec. 2020 – Evotec SE consolidated in k€ 2021 2020 Cash flows from operating activities Net income 215 510 6 278 Depreciation of property, plant and equipment 55 596 42 122 Amortisation of intangible assets 12 012 13 936 Depreciation of current assets 2 79
Slide 45: Your contact: Volker Braun
Your contact: Volker Braun SVP Head of Global Investor Relations & ESG +49.(0).40.560 81-775 +49.(0).151.1950 4058 volker.braun@evotec.com